688266.SH
泽璟制药-U
SSE · Healthcare · Biotechnology · CN
CNY 117.83
−8.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 810.5M | 533.0M | 386.4M | 302.3M |
| Cost of Revenue | 85.2M | 77.6M | 37.0M | 29.2M | 26.2M |
| Gross Profit | 1.5B | 732.9M | 496.0M | 357.2M | 276.1M |
| Operating Expenses | |||||
| R&D Expense | 420.0M | 429.9M | 388.0M | 496.3M | 497.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 74.1M | 74.2M | 58.2M | 16.6M | 86.3M |
| Selling & Marketing Expense | 507.6M | 465.4M | 271.4M | 250.5M | 227.7M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 988.1M | 948.3M | 689.9M | 749.5M | 799.5M |
| Cost and Expenses | 1.1B | 1.0B | 726.9M | 778.7M | 825.6M |
| Operating Income (EBIT) | 494.3M | (168.0M) | (155.0M) | (297.8M) | (485.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 493.4M | (168.7M) | (155.0M) | (299.1M) | (488.0M) |
| Income Tax Expense | (3.4M) | (3.5M) | (4.7M) | (3.9M) | (2.4M) |
| Bottom Line | |||||
| Net Income | 497.9M | (162.9M) | (137.8M) | (278.6M) | (457.3M) |
| Earnings from Cont. Ops | 496.8M | (165.1M) | (150.3M) | (295.1M) | (485.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 497.9M | (162.9M) | (137.8M) | (278.6M) | (457.3M) |
| Per Share | |||||
| Basic EPS | CN¥1.88 | (CN¥0.62) | (CN¥0.52) | (CN¥1.09) | (CN¥1.91) |
| Diluted EPS | CN¥1.88 | (CN¥0.62) | (CN¥0.52) | (CN¥1.09) | (CN¥1.91) |
| Revenue Per Share | CN¥5.85 | CN¥3.08 | CN¥2.01 | CN¥1.51 | CN¥1.26 |
| Shares | |||||
| Basic Shares Outstanding | 264.7M | 262.8M | 265.1M | 255.6M | 239.4M |
| Diluted Shares Outstanding | 264.7M | 262.8M | 265.1M | 255.6M | 239.4M |
| Profitability Metrics | |||||
| EBITDA | — | (120.1M) | (106.1M) | (249.5M) | (428.6M) |
| D&A | — | 47.9M | 49.0M | 48.3M | 56.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026